t
Aptamer Group plc issued 15,000 new ordinary shares on 9 January 2023 to satisfy the exercise of share options. Application for admission to AIM has been made, with admission expected on 12 January 2023. Following this, the total number of ordinary shares in issue and total voting rights will be 69,037,594, with no shares held in treasury.
| Date | 9 Jan 2023 |
| Time | 07:00:03 |
| Category | Capital structure |
| ID | 0184M |
9 January 2023
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces that it has issued 15,000 new ordinary shares in order to satisfy the exercise of share options.
Application for the admission of these shares to trading on AIM has been made and admission is expected on Thursday 12 January 2023, following which the total number of ordinary shares in issue and total voting rights will be 69,037,594. The Group does not hold any shares in treasury and, therefore, the above figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in the Company.
For further information, please contact:
Aptamer Group plc
Dr Arron Tolley +44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated Adviser
Andrew Emmott / Adam Dawes +44 (0) 20 3368 3550
Liberum Capital Limited - Broker
Richard Lindley / Ben Cryer / Cara Murphy +44 (0) 20 3100 2000
Consilium Strategic Communications
Matthew Neal / Chris Welsh / Lucy Featherstone +44 (0) 20 3709 5700
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.
Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145.0 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.
Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.